Natalia Niedziela
Overview
Explore the profile of Natalia Niedziela including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
182
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lis M, Niedziela N, Adamczyk-Zostawa J, Zalejska-Fiolka J, Szczygiel J, Sowa A, et al.
Curr Issues Mol Biol
. 2024 Dec;
46(12):14119-14131.
PMID: 39727973
Studies suggest that vitamin D (VitD) may reduce oxidative stress (OS) in multiple sclerosis (MS) patients. This study aimed to compare the effects of various VitD doses on OS in...
2.
Niedziela N, Nowak-Kiczmer M, Malciene L, Stasiolek M, Niedziela J, Czuba Z, et al.
Int J Mol Sci
. 2024 Oct;
25(19).
PMID: 39408830
Permanent inflammatory demyelinating and neurodegenerative processes lead to neurological disability in patients with multiple sclerosis (MS). The anti-inflammatory properties of vitamin D (VitD) are well established, but its role in...
3.
Niedziela N, Nowak-Kiczmer M, Malciene L, Stasiolek M, Zalejska-Fiolka J, Czuba Z, et al.
Diagnostics (Basel)
. 2024 Sep;
14(17).
PMID: 39272777
Background: Inflammatory demyelination and impaired recovery processes result in permanent neurodegeneration and neurological disability in patients with multiple sclerosis (MS). In terms of smoldering MS, chronic neuroinflammation develops in the...
4.
Lis M, Niedziela N, Adamczyk-Zostawa J, Zalejska-Fiolka J, Blachut M, Szczygiel J, et al.
Int J Mol Sci
. 2024 Jul;
25(14).
PMID: 39062835
There is increasing evidence that vitamin D (VitD) supplementation may reduce inflammation in individuals with multiple sclerosis (MS). The aim of this study was to evaluate the effect of different...
5.
Lis M, Niedziela N, Adamczyk-Zostawa J, Wierzbicki K, Czuba Z, Zalejska-Fiolka J, et al.
Biomedicines
. 2024 Jul;
12(7).
PMID: 39062153
(1) Background: Studies indicate that vitamin D (VitD) may reduce inflammation in multiple sclerosis (MS). The aim of the study was to assess the effect of supplementation with different doses...
6.
Niedziela N, Kalinowska A, Kulakowska A, Mirowska-Guzel D, Rejdak K, Siger M, et al.
Neurol Neurochir Pol
. 2024 Jun;
58(3):245-255.
PMID: 38842128
Introduction: Assessment of the clinical course, neuroimaging and histopathological changes suggests that multiple sclerosis (MS) should not be defined merely as a focal inflammatory disease of the central nervous system...
7.
Nowak-Kiczmer M, Niedziela N, Czuba Z, Sowa P, Wierzbicki K, Lubczynski M, et al.
Neurol Res
. 2024 May;
46(6):495-504.
PMID: 38697017
Objectives: Multiple sclerosis (MS) is a chronic autoimmune inflammatory disease. Patients with relapsing-remitting MS (RRMS) and secondary progressive MS (SPMS) differ in their responses to treatment; therefore, the correct diagnosis...
8.
Podlecka-Pietowska A, Sierdzinski J, Nojszewska M, Stawicki J, Bartosik-Psujek H, Lech B, et al.
Neurol Neurochir Pol
. 2024 Jan;
58(1):112-119.
PMID: 38251955
Clinical Rationale For The Study: The rapid spread of SARS-CoV-2 throughout the world has highlighted the importance of vaccinations to control the pandemic and to protect people at risk for...
9.
Nowak-Kiczmer M, Niedziela N, Czuba Z, Sowa P, Wierzbicki K, Lubczynski M, et al.
Mult Scler Relat Disord
. 2023 Sep;
79:105004.
PMID: 37738756
Introduction: Multiple sclerosis (MS) is a chronic, inflammatory demyelinating disease of the central nervous system. Primary progressive MS (PPMS) is diagnosed in approximately 10-15 % of MS patients. Disease-modifying therapies...
10.
Niedziela N, Zimnol A, Lubczynski M, Szymbara P, Kubicka-Baczyk K, Jaroszewicz J, et al.
Pol Merkur Lekarski
. 2023 Aug;
51(3):189-193.
PMID: 37589101
Objective: Aim: Multiple sclerosis (MS) is a chronic inflammatory neurodegenerative disease resulting in cognitive impairment, physical disabilities, and neurological symptoms. Ocrelizumab is an effective drug used in MS treatment. However,...